Mark Haden
Corporate Officer/Principal at CLEARMIND MEDICINE INC.
Net worth: 150 $ as of 2024-05-30
Profile
Mark Haden is currently the Vice President of Business Development at Clearmind Medicine, Inc. He previously worked as the Director of Clinical Trials at Psygen Labs, Inc. from 2021 to 2022 and as the Executive Director at Multidisciplinary Association for Psychedelic Studies Canada from 2017 to 2021.
Haden received his undergraduate and graduate degrees from the University of British Columbia.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CLEARMIND MEDICINE INC.
0.00% | 2023-10-30 | 133 ( 0.00% ) | 150 $ | 2024-05-30 |
Mark Haden active positions
| Companies | Position | Start |
|---|---|---|
| CLEARMIND MEDICINE INC. | Corporate Officer/Principal | 2021-06-30 |
Former positions of Mark Haden
| Companies | Position | End |
|---|---|---|
Psygen Labs, Inc.
 Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Corporate Officer/Principal | 2022-02-28 |
Training of Mark Haden
| University of British Columbia | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CLEARMIND MEDICINE INC. | Health Technology |
| Private companies | 1 |
|---|---|
Psygen Labs, Inc.
Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Health Technology |
- Stock Market
- Insiders
- Mark Haden
